REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...
On November 2, 2025, the FDA issued a complete response letter (CRL) for Alvotech’s abbreviated Biologics License Application (aBLA) for its proposed Simponi ® (golimumab) biosimilar AVT05. The CRL ...
REYKJAVIK, ICELAND and LONDON, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients ...
REYKJAVIK, Iceland, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved golimumab for the treatment of children with moderately to severely active ulcerative ...
FDA biosimilar approvals reached a record 19 in 2024, with projections indicating that 2025 could surpass this milestone trend. This presents a golden opportunity for Contract Manufacturing ...
Dr. Reddy’s Laboratories RDY and China-based Bio-Thera Solutions announced that they have entered into commercialization and license agreements for BAT2206, a proposed biosimilar of Johnson & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback